Story thread · 19 reports / 10 sources

Argenx Expands Immunology Portfolio with $2.2B Buyout of Forte Biosciences

genengnews.com · 14dShare

Earlier this month Forte announced positive results for its lead candidate FB102, from a Phase Ib trial assessing the anti-CD122 monoclonal antibody in vitiligo. FB102 achieved a 29.6% mean Facial Vitiligo Area Scoring Index (FVASI) improvement from baseline at week 24 (p-value = 0.020), with statistically significant improvements seen as early as Day 64 after dosing (p=0.023), continuing through week 24 after completion of the 12-week treatment period. The post Argenx Expands Immunology Portfolio with $2.2B Buyout of Forte Biosciences appeared first on GEN - Genetic Engineering and Biotechnology News .

First report: argenx to acquire Forte Biosciences for $2.2 billion in cash — investing.com, 15d